A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Solid Tumors|Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer
Interventions: DRUG: IDE-161
Sponsor: IDEAYA Biosciences